Luisa Mestroni
Concepts (588)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cardiomyopathy, Dilated | 94 | 2025 | 381 | 11.370 |
Why?
| Cardiomyopathies | 38 | 2025 | 336 | 6.710 |
Why?
| Arrhythmogenic Right Ventricular Dysplasia | 24 | 2025 | 38 | 5.890 |
Why?
| Arrhythmias, Cardiac | 34 | 2025 | 315 | 5.120 |
Why?
| Myocytes, Cardiac | 28 | 2024 | 496 | 4.010 |
Why?
| Death, Sudden, Cardiac | 21 | 2025 | 179 | 3.080 |
Why?
| Heart Failure | 35 | 2025 | 2147 | 2.650 |
Why?
| Lamin Type A | 18 | 2023 | 48 | 2.520 |
Why?
| Filamins | 8 | 2025 | 28 | 2.490 |
Why?
| Cardiomyopathy, Hypertrophic | 16 | 2025 | 132 | 2.250 |
Why?
| Phenotype | 35 | 2025 | 3074 | 2.080 |
Why?
| Mutation | 40 | 2023 | 3715 | 1.810 |
Why?
| Myocardium | 25 | 2024 | 976 | 1.790 |
Why?
| Nanotubes, Carbon | 6 | 2022 | 42 | 1.690 |
Why?
| Precision Medicine | 6 | 2024 | 387 | 1.590 |
Why?
| Tissue Engineering | 7 | 2023 | 396 | 1.550 |
Why?
| Muscle Proteins | 8 | 2025 | 220 | 1.460 |
Why?
| Genetic Predisposition to Disease | 23 | 2024 | 2281 | 1.420 |
Why?
| Electrocardiography | 18 | 2025 | 606 | 1.380 |
Why?
| Genetic Testing | 14 | 2024 | 428 | 1.210 |
Why?
| Ventricular Remodeling | 7 | 2025 | 255 | 1.210 |
Why?
| Genetic Variation | 6 | 2021 | 937 | 1.200 |
Why?
| Tissue Scaffolds | 6 | 2022 | 200 | 1.190 |
Why?
| Fibroblasts | 7 | 2025 | 944 | 1.120 |
Why?
| Glycogen Storage Disease Type IIb | 8 | 2025 | 25 | 1.080 |
Why?
| Cell Adhesion | 11 | 2021 | 451 | 1.070 |
Why?
| Heart | 10 | 2021 | 637 | 1.060 |
Why?
| Induced Pluripotent Stem Cells | 5 | 2024 | 221 | 1.040 |
Why?
| Humans | 199 | 2025 | 129212 | 1.030 |
Why?
| Sarcomeres | 7 | 2024 | 92 | 1.000 |
Why?
| Connectin | 10 | 2022 | 31 | 0.940 |
Why?
| Valsartan | 5 | 2025 | 27 | 0.880 |
Why?
| Amyloid Neuropathies, Familial | 1 | 2023 | 14 | 0.860 |
Why?
| Pharmacogenetics | 5 | 2014 | 175 | 0.850 |
Why?
| Ventricular Function, Left | 11 | 2025 | 526 | 0.830 |
Why?
| Prognosis | 21 | 2025 | 3791 | 0.790 |
Why?
| Desmoplakins | 4 | 2025 | 19 | 0.780 |
Why?
| Heart Ventricles | 13 | 2021 | 779 | 0.780 |
Why?
| Stroke Volume | 17 | 2025 | 590 | 0.780 |
Why?
| Mutation, Missense | 9 | 2021 | 317 | 0.780 |
Why?
| Pedigree | 29 | 2021 | 487 | 0.760 |
Why?
| Gold | 3 | 2020 | 118 | 0.740 |
Why?
| Microscopy, Atomic Force | 11 | 2022 | 116 | 0.710 |
Why?
| Risk Assessment | 14 | 2025 | 3234 | 0.690 |
Why?
| Ventricular Dysfunction, Left | 8 | 2024 | 383 | 0.660 |
Why?
| Male | 97 | 2025 | 63491 | 0.660 |
Why?
| Middle Aged | 63 | 2025 | 31075 | 0.650 |
Why?
| Genetic Therapy | 2 | 2017 | 292 | 0.650 |
Why?
| Metal Nanoparticles | 2 | 2020 | 82 | 0.630 |
Why?
| Adult | 69 | 2025 | 35464 | 0.620 |
Why?
| Female | 93 | 2025 | 68600 | 0.590 |
Why?
| Clinical Trials, Phase II as Topic | 2 | 2022 | 72 | 0.590 |
Why?
| Dystrophin | 10 | 2020 | 34 | 0.580 |
Why?
| Plakophilins | 4 | 2023 | 4 | 0.570 |
Why?
| Ventricular Function | 1 | 2017 | 61 | 0.560 |
Why?
| Heterozygote | 10 | 2025 | 272 | 0.550 |
Why?
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2016 | 4 | 0.540 |
Why?
| Rho Guanine Nucleotide Exchange Factors | 1 | 2016 | 22 | 0.540 |
Why?
| Registries | 16 | 2025 | 1886 | 0.520 |
Why?
| Laminin | 1 | 2016 | 69 | 0.510 |
Why?
| Biomimetics | 1 | 2016 | 41 | 0.500 |
Why?
| Protein Kinases | 4 | 2013 | 318 | 0.500 |
Why?
| Multicenter Studies as Topic | 1 | 2017 | 286 | 0.500 |
Why?
| Defibrillators, Implantable | 4 | 2021 | 297 | 0.490 |
Why?
| Rats | 13 | 2024 | 5462 | 0.490 |
Why?
| Cell Adhesion Molecules | 2 | 2023 | 173 | 0.480 |
Why?
| Embryonic Stem Cells | 1 | 2016 | 118 | 0.480 |
Why?
| DNA Mutational Analysis | 11 | 2018 | 387 | 0.480 |
Why?
| Hydrogels | 2 | 2019 | 638 | 0.480 |
Why?
| Polymers | 4 | 2022 | 479 | 0.470 |
Why?
| Genetic Heterogeneity | 2 | 2009 | 58 | 0.470 |
Why?
| Animals | 38 | 2025 | 35219 | 0.470 |
Why?
| Echocardiography | 11 | 2025 | 626 | 0.460 |
Why?
| Receptors, Endothelin | 2 | 2014 | 50 | 0.460 |
Why?
| Cardiovascular Agents | 2 | 2025 | 156 | 0.450 |
Why?
| Ventricular Dysfunction, Right | 4 | 2023 | 231 | 0.450 |
Why?
| Receptors, Adrenergic | 1 | 2014 | 34 | 0.450 |
Why?
| Fibrosis | 5 | 2024 | 520 | 0.440 |
Why?
| Tachycardia, Ventricular | 5 | 2024 | 167 | 0.440 |
Why?
| Connexin 43 | 1 | 2014 | 29 | 0.440 |
Why?
| Lysine | 1 | 2016 | 286 | 0.430 |
Why?
| src-Family Kinases | 1 | 2014 | 96 | 0.420 |
Why?
| Genes, Dominant | 12 | 2007 | 92 | 0.400 |
Why?
| Cytoskeleton | 7 | 2020 | 182 | 0.400 |
Why?
| Cardiac Resynchronization Therapy | 2 | 2024 | 45 | 0.400 |
Why?
| Randomized Controlled Trials as Topic | 2 | 2022 | 1360 | 0.390 |
Why?
| Disease Progression | 6 | 2025 | 2622 | 0.390 |
Why?
| Genetic Association Studies | 5 | 2021 | 360 | 0.380 |
Why?
| Disease Management | 4 | 2021 | 586 | 0.380 |
Why?
| Hypertrophy, Left Ventricular | 3 | 2025 | 126 | 0.370 |
Why?
| Human Genome Project | 1 | 2011 | 15 | 0.370 |
Why?
| Myocardial Infarction | 2 | 2019 | 1019 | 0.350 |
Why?
| Extracellular Matrix | 3 | 2025 | 503 | 0.350 |
Why?
| Electrocardiography, Ambulatory | 4 | 2025 | 57 | 0.350 |
Why?
| Nuclear Proteins | 2 | 2009 | 663 | 0.350 |
Why?
| Gene Expression Regulation | 4 | 2020 | 2543 | 0.340 |
Why?
| Genetic Linkage | 10 | 2001 | 299 | 0.330 |
Why?
| Risk Factors | 13 | 2024 | 9747 | 0.320 |
Why?
| Cell Differentiation | 2 | 2017 | 1899 | 0.310 |
Why?
| Genome, Human | 1 | 2011 | 393 | 0.310 |
Why?
| Retrospective Studies | 19 | 2025 | 14488 | 0.310 |
Why?
| Muscular Dystrophies | 2 | 2018 | 35 | 0.310 |
Why?
| Cells, Cultured | 9 | 2021 | 4072 | 0.310 |
Why?
| Italy | 13 | 2020 | 98 | 0.300 |
Why?
| Molecular Biology | 4 | 1997 | 55 | 0.300 |
Why?
| Desmosomes | 3 | 2019 | 21 | 0.300 |
Why?
| Chromosome Mapping | 8 | 1997 | 504 | 0.300 |
Why?
| Magnetic Resonance Imaging, Cine | 3 | 2025 | 185 | 0.290 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 3 | 2025 | 36 | 0.280 |
Why?
| Lamins | 2 | 2004 | 5 | 0.280 |
Why?
| Myosin Heavy Chains | 3 | 2013 | 170 | 0.280 |
Why?
| DNA Methylation | 2 | 2025 | 607 | 0.280 |
Why?
| Heart Rate | 3 | 2025 | 800 | 0.280 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2020 | 511 | 0.270 |
Why?
| Adolescent | 29 | 2025 | 20371 | 0.270 |
Why?
| Repressor Proteins | 1 | 2009 | 406 | 0.250 |
Why?
| Genotype | 6 | 2022 | 1839 | 0.250 |
Why?
| Myocarditis | 5 | 2022 | 98 | 0.250 |
Why?
| Double-Blind Method | 5 | 2025 | 1871 | 0.250 |
Why?
| Indazoles | 2 | 2022 | 65 | 0.240 |
Why?
| Ventricular Myosins | 1 | 2005 | 36 | 0.240 |
Why?
| Animals, Newborn | 5 | 2022 | 826 | 0.240 |
Why?
| Chromosomes, Human, Y | 1 | 2025 | 20 | 0.240 |
Why?
| Heart Transplantation | 7 | 2020 | 721 | 0.240 |
Why?
| Materials Testing | 2 | 2019 | 346 | 0.230 |
Why?
| Rats, Sprague-Dawley | 3 | 2021 | 2387 | 0.230 |
Why?
| Exercise Test | 5 | 2024 | 613 | 0.220 |
Why?
| Myofibroblasts | 2 | 2025 | 121 | 0.220 |
Why?
| Muscular Dystrophy, Emery-Dreifuss | 1 | 2023 | 3 | 0.220 |
Why?
| Cardiomyopathy, Hypertrophic, Familial | 1 | 2004 | 16 | 0.220 |
Why?
| Desmin | 2 | 2018 | 24 | 0.220 |
Why?
| Rheology | 1 | 2024 | 90 | 0.220 |
Why?
| X Chromosome | 8 | 2001 | 52 | 0.220 |
Why?
| Prealbumin | 1 | 2023 | 28 | 0.220 |
Why?
| Syncope | 1 | 2024 | 50 | 0.220 |
Why?
| Tachycardia | 1 | 2023 | 57 | 0.220 |
Why?
| Predictive Value of Tests | 3 | 2020 | 1944 | 0.210 |
Why?
| Spheroids, Cellular | 1 | 2024 | 77 | 0.210 |
Why?
| NAD | 1 | 2023 | 75 | 0.210 |
Why?
| AMP-Activated Protein Kinases | 2 | 2016 | 189 | 0.210 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2004 | 575 | 0.210 |
Why?
| Genetic Markers | 4 | 2018 | 338 | 0.210 |
Why?
| Progeria | 1 | 2022 | 5 | 0.210 |
Why?
| Ethylenediamines | 1 | 2022 | 6 | 0.200 |
Why?
| Ventricular Function, Right | 2 | 2023 | 276 | 0.200 |
Why?
| Point Mutation | 4 | 2011 | 225 | 0.200 |
Why?
| Time Factors | 11 | 2025 | 6549 | 0.200 |
Why?
| Sex Characteristics | 2 | 2025 | 732 | 0.200 |
Why?
| Exercise Tolerance | 1 | 2024 | 273 | 0.190 |
Why?
| Myocardial Contraction | 4 | 2023 | 335 | 0.190 |
Why?
| Aortic Valve Stenosis | 1 | 2025 | 218 | 0.190 |
Why?
| Chromosomes, Human, Pair 9 | 3 | 1997 | 39 | 0.190 |
Why?
| Aged | 27 | 2025 | 22030 | 0.190 |
Why?
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2022 | 45 | 0.190 |
Why?
| Young Adult | 13 | 2025 | 12396 | 0.190 |
Why?
| Aortic Valve | 1 | 2025 | 348 | 0.190 |
Why?
| Microtechnology | 1 | 2021 | 7 | 0.190 |
Why?
| Chagas Cardiomyopathy | 1 | 2021 | 21 | 0.190 |
Why?
| Chagas Disease | 1 | 2021 | 35 | 0.180 |
Why?
| Heart Murmurs | 1 | 2021 | 12 | 0.180 |
Why?
| ADAM10 Protein | 1 | 2021 | 30 | 0.180 |
Why?
| Actinin | 1 | 2020 | 13 | 0.180 |
Why?
| Gamma Rays | 1 | 2021 | 54 | 0.180 |
Why?
| NAV1.5 Voltage-Gated Sodium Channel | 3 | 2017 | 12 | 0.170 |
Why?
| Genomics | 2 | 2017 | 715 | 0.170 |
Why?
| Mechanical Phenomena | 1 | 2021 | 84 | 0.170 |
Why?
| Combined Modality Therapy | 2 | 2021 | 1202 | 0.170 |
Why?
| Neuromuscular Diseases | 1 | 2002 | 105 | 0.170 |
Why?
| Adrenergic beta-Antagonists | 4 | 2025 | 320 | 0.170 |
Why?
| Amyloid Precursor Protein Secretases | 1 | 2021 | 79 | 0.170 |
Why?
| Epidermolysis Bullosa Simplex | 1 | 2020 | 10 | 0.170 |
Why?
| Heart Diseases | 1 | 2023 | 350 | 0.170 |
Why?
| Ectodermal Dysplasia | 1 | 2020 | 16 | 0.170 |
Why?
| Heart Conduction System | 3 | 2016 | 95 | 0.170 |
Why?
| Elastic Modulus | 5 | 2022 | 123 | 0.170 |
Why?
| Muscular Dystrophy, Duchenne | 1 | 2021 | 89 | 0.170 |
Why?
| Radiation Injuries | 1 | 2021 | 135 | 0.160 |
Why?
| Mice | 12 | 2022 | 16861 | 0.160 |
Why?
| Nanostructures | 1 | 2020 | 100 | 0.160 |
Why?
| Nanotechnology | 1 | 2020 | 122 | 0.160 |
Why?
| Ankyrins | 1 | 2019 | 9 | 0.160 |
Why?
| Elasticity | 2 | 2017 | 196 | 0.160 |
Why?
| Muscular Diseases | 1 | 2000 | 107 | 0.160 |
Why?
| High-Throughput Nucleotide Sequencing | 4 | 2018 | 487 | 0.160 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2021 | 209 | 0.160 |
Why?
| Gene Deletion | 2 | 1997 | 378 | 0.160 |
Why?
| Treatment Outcome | 10 | 2025 | 10189 | 0.160 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2021 | 202 | 0.160 |
Why?
| Membrane Proteins | 2 | 2021 | 1115 | 0.150 |
Why?
| Immunity, Cellular | 2 | 2018 | 264 | 0.150 |
Why?
| Biopsy | 4 | 2022 | 1087 | 0.150 |
Why?
| Actin Cytoskeleton | 2 | 2021 | 104 | 0.150 |
Why?
| Atrial Fibrillation | 1 | 2003 | 376 | 0.150 |
Why?
| Alleles | 1 | 2021 | 845 | 0.150 |
Why?
| Cytochalasin D | 2 | 2015 | 4 | 0.150 |
Why?
| Coculture Techniques | 1 | 2019 | 226 | 0.150 |
Why?
| Cell Nucleus | 3 | 2019 | 582 | 0.150 |
Why?
| DNA | 2 | 2016 | 1399 | 0.150 |
Why?
| Sodium Channels | 2 | 2011 | 63 | 0.150 |
Why?
| Intermediate Filaments | 1 | 2017 | 27 | 0.150 |
Why?
| Contrast Media | 1 | 2021 | 391 | 0.150 |
Why?
| Skin Physiological Phenomena | 1 | 2017 | 24 | 0.140 |
Why?
| Child | 18 | 2025 | 20853 | 0.140 |
Why?
| Follow-Up Studies | 14 | 2024 | 4886 | 0.140 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 269 | 0.140 |
Why?
| Cardiac Imaging Techniques | 1 | 2017 | 20 | 0.140 |
Why?
| Wnt Signaling Pathway | 1 | 2019 | 168 | 0.140 |
Why?
| Family Health | 2 | 2011 | 197 | 0.140 |
Why?
| Ion Channels | 1 | 2018 | 130 | 0.140 |
Why?
| Gelatin | 1 | 2017 | 42 | 0.140 |
Why?
| Biomechanical Phenomena | 4 | 2024 | 763 | 0.140 |
Why?
| Muscle, Skeletal | 6 | 2005 | 1614 | 0.140 |
Why?
| Myocardial Ischemia | 1 | 2018 | 250 | 0.140 |
Why?
| Mechanotransduction, Cellular | 1 | 2018 | 110 | 0.130 |
Why?
| Vasodilator Agents | 4 | 1988 | 326 | 0.130 |
Why?
| Internationality | 1 | 2017 | 149 | 0.130 |
Why?
| Odds Ratio | 2 | 2017 | 1023 | 0.130 |
Why?
| Troponin T | 2 | 2013 | 57 | 0.130 |
Why?
| Transcriptome | 2 | 2020 | 885 | 0.130 |
Why?
| Molecular Diagnostic Techniques | 1 | 2017 | 98 | 0.130 |
Why?
| DNA Damage | 1 | 2019 | 384 | 0.130 |
Why?
| Prevalence | 8 | 2021 | 2559 | 0.130 |
Why?
| MicroRNAs | 2 | 2020 | 675 | 0.130 |
Why?
| Exome | 2 | 2017 | 220 | 0.130 |
Why?
| Multigene Family | 1 | 2017 | 199 | 0.130 |
Why?
| Shear Strength | 1 | 2016 | 67 | 0.130 |
Why?
| Keratinocytes | 1 | 2017 | 241 | 0.130 |
Why?
| Cell Proliferation | 4 | 2021 | 2388 | 0.130 |
Why?
| Multivariate Analysis | 3 | 2017 | 1500 | 0.130 |
Why?
| Quality of Life | 3 | 2024 | 2693 | 0.130 |
Why?
| Wolff-Parkinson-White Syndrome | 1 | 2016 | 19 | 0.130 |
Why?
| Chromosomes, Human, Pair 14 | 4 | 1996 | 19 | 0.130 |
Why?
| Nanofibers | 1 | 2015 | 20 | 0.130 |
Why?
| Treatment Failure | 1 | 2017 | 339 | 0.120 |
Why?
| Cross-Sectional Studies | 4 | 2019 | 5057 | 0.120 |
Why?
| RNA-Binding Proteins | 1 | 2019 | 387 | 0.120 |
Why?
| Polyesters | 1 | 2015 | 72 | 0.120 |
Why?
| Proteomics | 1 | 2022 | 1061 | 0.120 |
Why?
| Chromosomes | 1 | 1995 | 101 | 0.120 |
Why?
| Genotyping Techniques | 2 | 2012 | 72 | 0.120 |
Why?
| Magnetic Resonance Imaging | 5 | 2025 | 3390 | 0.110 |
Why?
| Spectrum Analysis | 1 | 2015 | 89 | 0.110 |
Why?
| Logistic Models | 2 | 2017 | 1983 | 0.110 |
Why?
| Cell Membrane | 1 | 2018 | 730 | 0.110 |
Why?
| Propanolamines | 2 | 2009 | 97 | 0.110 |
Why?
| Heart Aneurysm | 1 | 1994 | 10 | 0.110 |
Why?
| Cell Culture Techniques | 1 | 2016 | 345 | 0.110 |
Why?
| Polymerase Chain Reaction | 7 | 2008 | 1036 | 0.110 |
Why?
| Catheter Ablation | 2 | 2014 | 334 | 0.110 |
Why?
| Apoptosis Regulatory Proteins | 1 | 2014 | 182 | 0.110 |
Why?
| DNA, Mitochondrial | 3 | 2004 | 191 | 0.110 |
Why?
| Molecular Sequence Data | 6 | 2014 | 2830 | 0.110 |
Why?
| Genetics | 1 | 2013 | 25 | 0.110 |
Why?
| Autophagy | 1 | 2016 | 267 | 0.110 |
Why?
| Accessory Atrioventricular Bundle | 1 | 2013 | 13 | 0.110 |
Why?
| Cell Enlargement | 1 | 2013 | 6 | 0.110 |
Why?
| Giant Cells | 1 | 2013 | 23 | 0.110 |
Why?
| Pancreatic Neoplasms | 1 | 2021 | 879 | 0.100 |
Why?
| Amino Acid Sequence | 3 | 2016 | 2056 | 0.100 |
Why?
| Tachycardia, Supraventricular | 1 | 2013 | 44 | 0.100 |
Why?
| Monitoring, Physiologic | 2 | 2021 | 268 | 0.100 |
Why?
| Atrioventricular Block | 1 | 2013 | 35 | 0.100 |
Why?
| Equipment Failure Analysis | 1 | 2013 | 131 | 0.100 |
Why?
| Action Potentials | 1 | 2016 | 485 | 0.100 |
Why?
| Cohort Studies | 7 | 2022 | 5408 | 0.100 |
Why?
| Anti-Arrhythmia Agents | 4 | 2021 | 110 | 0.100 |
Why?
| American Heart Association | 1 | 2013 | 296 | 0.100 |
Why?
| Surface Properties | 1 | 2013 | 398 | 0.100 |
Why?
| Particle Size | 1 | 2013 | 355 | 0.100 |
Why?
| Electrophysiological Phenomena | 1 | 2012 | 54 | 0.100 |
Why?
| Nuclear Lamina | 2 | 2020 | 10 | 0.090 |
Why?
| Survival Rate | 6 | 2021 | 1874 | 0.090 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 398 | 0.090 |
Why?
| Prospective Studies | 9 | 2023 | 7103 | 0.090 |
Why?
| Kaplan-Meier Estimate | 4 | 2015 | 857 | 0.090 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1705 | 0.090 |
Why?
| Penetrance | 1 | 2011 | 27 | 0.090 |
Why?
| Sequence Analysis, DNA | 2 | 2012 | 778 | 0.090 |
Why?
| Biomarkers | 2 | 2023 | 3968 | 0.090 |
Why?
| Equipment Design | 1 | 2013 | 513 | 0.090 |
Why?
| Chromosome Disorders | 3 | 1997 | 40 | 0.090 |
Why?
| Sex Chromosome Aberrations | 3 | 1997 | 63 | 0.090 |
Why?
| Sensitivity and Specificity | 6 | 2015 | 1834 | 0.090 |
Why?
| Graft Rejection | 2 | 2004 | 597 | 0.090 |
Why?
| Bundle-Branch Block | 2 | 2024 | 30 | 0.090 |
Why?
| Chromosome Aberrations | 3 | 1997 | 150 | 0.090 |
Why?
| Syndrome | 1 | 2011 | 339 | 0.090 |
Why?
| Practice Guidelines as Topic | 2 | 2015 | 1493 | 0.090 |
Why?
| Diagnosis, Differential | 4 | 2020 | 1424 | 0.080 |
Why?
| Nanoparticles | 1 | 2014 | 373 | 0.080 |
Why?
| Cell Division | 1 | 2012 | 796 | 0.080 |
Why?
| Robotics | 1 | 2011 | 90 | 0.080 |
Why?
| Sarcoidosis | 1 | 2012 | 155 | 0.080 |
Why?
| Family | 2 | 2014 | 653 | 0.080 |
Why?
| Gene Frequency | 3 | 2017 | 503 | 0.080 |
Why?
| Immunosuppressive Agents | 2 | 2004 | 840 | 0.080 |
Why?
| Genetic Counseling | 2 | 2009 | 72 | 0.080 |
Why?
| Chromosomes, Human, Pair 3 | 3 | 2004 | 48 | 0.080 |
Why?
| Sequence Deletion | 3 | 2014 | 178 | 0.080 |
Why?
| Models, Biological | 3 | 2024 | 1718 | 0.080 |
Why?
| Disease-Free Survival | 3 | 2015 | 647 | 0.080 |
Why?
| Enterovirus | 3 | 1994 | 78 | 0.080 |
Why?
| Cardiac Surgical Procedures | 1 | 2014 | 498 | 0.080 |
Why?
| RNA | 3 | 2023 | 883 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 5408 | 0.080 |
Why?
| Rats, Wistar | 2 | 2024 | 440 | 0.080 |
Why?
| Global Health | 2 | 2014 | 329 | 0.080 |
Why?
| United States | 8 | 2021 | 13873 | 0.080 |
Why?
| Immunohistochemistry | 3 | 2018 | 1696 | 0.080 |
Why?
| Cardiomyopathy, Restrictive | 4 | 1999 | 9 | 0.070 |
Why?
| Organic Cation Transport Proteins | 1 | 2008 | 30 | 0.070 |
Why?
| Amiodarone | 4 | 2011 | 24 | 0.070 |
Why?
| Carnitine | 1 | 2008 | 76 | 0.070 |
Why?
| Endothelin-1 | 1 | 2009 | 179 | 0.070 |
Why?
| Chromosomes, Human, Pair 1 | 2 | 1997 | 71 | 0.070 |
Why?
| Endocardium | 3 | 1999 | 33 | 0.070 |
Why?
| Retinitis Pigmentosa | 1 | 2006 | 20 | 0.070 |
Why?
| Consensus | 2 | 2019 | 612 | 0.060 |
Why?
| Disease Models, Animal | 4 | 2021 | 4049 | 0.060 |
Why?
| Lysosomal-Associated Membrane Protein 2 | 3 | 2014 | 28 | 0.060 |
Why?
| Myopia | 1 | 2006 | 47 | 0.060 |
Why?
| Europe | 2 | 2018 | 362 | 0.060 |
Why?
| Gene Expression | 3 | 2008 | 1469 | 0.060 |
Why?
| Child, Preschool | 6 | 2017 | 10507 | 0.060 |
Why?
| Molecular Epidemiology | 1 | 2005 | 63 | 0.060 |
Why?
| Autoimmune Diseases | 3 | 2001 | 426 | 0.060 |
Why?
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 33 | 0.060 |
Why?
| Case-Control Studies | 2 | 2018 | 3372 | 0.060 |
Why?
| Conserved Sequence | 1 | 2005 | 227 | 0.060 |
Why?
| Prenatal Diagnosis | 1 | 2006 | 190 | 0.060 |
Why?
| Methylation | 1 | 2025 | 230 | 0.060 |
Why?
| Aged, 80 and over | 4 | 2013 | 7061 | 0.060 |
Why?
| NIH 3T3 Cells | 2 | 2015 | 141 | 0.060 |
Why?
| Hemodynamics | 9 | 1992 | 1086 | 0.060 |
Why?
| Homozygote | 2 | 2015 | 193 | 0.060 |
Why?
| Potassium Channels | 1 | 2025 | 147 | 0.060 |
Why?
| Osteoblasts | 1 | 2025 | 124 | 0.060 |
Why?
| Primary Prevention | 2 | 2016 | 188 | 0.060 |
Why?
| Cell Shape | 2 | 2015 | 55 | 0.060 |
Why?
| Virus Diseases | 3 | 1998 | 211 | 0.060 |
Why?
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2024 | 35 | 0.050 |
Why?
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 37 | 0.050 |
Why?
| Genome-Wide Association Study | 2 | 2023 | 1332 | 0.050 |
Why?
| Haplotypes | 3 | 2013 | 475 | 0.050 |
Why?
| Clinical Trials as Topic | 2 | 2004 | 1004 | 0.050 |
Why?
| Amino Acid Substitution | 1 | 2004 | 282 | 0.050 |
Why?
| Transplantation, Homologous | 1 | 2004 | 401 | 0.050 |
Why?
| Transforming Growth Factors | 1 | 2023 | 2 | 0.050 |
Why?
| Signal Transduction | 3 | 2024 | 4913 | 0.050 |
Why?
| Cataract | 1 | 2006 | 208 | 0.050 |
Why?
| Codon, Nonsense | 1 | 2023 | 39 | 0.050 |
Why?
| Antigens, CD | 2 | 2017 | 488 | 0.050 |
Why?
| Calcinosis | 1 | 2025 | 230 | 0.050 |
Why?
| Mitogen-Activated Protein Kinase 14 | 1 | 2022 | 6 | 0.050 |
Why?
| Oxidative Phosphorylation | 1 | 2023 | 187 | 0.050 |
Why?
| Dogs | 1 | 2023 | 378 | 0.050 |
Why?
| Mass Screening | 1 | 2010 | 1147 | 0.050 |
Why?
| Clinical Trials, Phase III as Topic | 1 | 2022 | 93 | 0.050 |
Why?
| Pregnancy | 3 | 2022 | 6384 | 0.050 |
Why?
| Natriuretic Peptide, Brain | 1 | 2022 | 99 | 0.050 |
Why?
| Glycolysis | 1 | 2023 | 309 | 0.050 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2024 | 231 | 0.050 |
Why?
| Actins | 1 | 2024 | 408 | 0.050 |
Why?
| Genetic Background | 1 | 2021 | 10 | 0.050 |
Why?
| Optical Tweezers | 1 | 2021 | 21 | 0.050 |
Why?
| Cardiovascular Diseases | 1 | 2013 | 2001 | 0.050 |
Why?
| RNA, Messenger | 3 | 2020 | 2702 | 0.050 |
Why?
| Metoprolol | 2 | 1999 | 39 | 0.050 |
Why?
| Pyrroles | 1 | 2022 | 202 | 0.050 |
Why?
| Nanotubes | 1 | 2021 | 43 | 0.050 |
Why?
| Cell Line | 2 | 2019 | 2777 | 0.040 |
Why?
| Antigens, Neoplasm | 1 | 2023 | 309 | 0.040 |
Why?
| Apoptosis | 2 | 2021 | 2501 | 0.040 |
Why?
| Base Sequence | 5 | 2014 | 2141 | 0.040 |
Why?
| Ephrin-B2 | 1 | 2021 | 50 | 0.040 |
Why?
| Electric Conductivity | 1 | 2020 | 94 | 0.040 |
Why?
| Gadolinium | 1 | 2021 | 77 | 0.040 |
Why?
| Transforming Growth Factor beta | 1 | 2023 | 457 | 0.040 |
Why?
| Transfection | 2 | 2017 | 908 | 0.040 |
Why?
| Ferric Compounds | 1 | 2020 | 47 | 0.040 |
Why?
| RNA, Viral | 2 | 1994 | 619 | 0.040 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2022 | 538 | 0.040 |
Why?
| Computational Biology | 2 | 2015 | 597 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2023 | 1026 | 0.040 |
Why?
| Denmark | 1 | 2019 | 44 | 0.040 |
Why?
| Fluorescent Antibody Technique | 2 | 2018 | 376 | 0.040 |
Why?
| HeLa Cells | 2 | 2015 | 607 | 0.040 |
Why?
| Maleimides | 1 | 2019 | 21 | 0.040 |
Why?
| Brazil | 1 | 2019 | 154 | 0.040 |
Why?
| Cell Plasticity | 1 | 2019 | 27 | 0.040 |
Why?
| Principal Component Analysis | 1 | 2020 | 186 | 0.040 |
Why?
| Nucleic Acid Amplification Techniques | 1 | 2019 | 32 | 0.040 |
Why?
| Fatal Outcome | 1 | 2020 | 300 | 0.040 |
Why?
| E2F Transcription Factors | 1 | 2019 | 59 | 0.040 |
Why?
| Sex Factors | 1 | 2025 | 1961 | 0.040 |
Why?
| Transforming Growth Factor beta1 | 1 | 2020 | 157 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2021 | 939 | 0.040 |
Why?
| Regeneration | 1 | 2020 | 179 | 0.040 |
Why?
| Carbazoles | 1 | 1999 | 84 | 0.040 |
Why?
| Heterochromatin | 1 | 2019 | 41 | 0.040 |
Why?
| CpG Islands | 1 | 2019 | 152 | 0.040 |
Why?
| Canada | 1 | 2019 | 347 | 0.040 |
Why?
| Protein Conformation, alpha-Helical | 1 | 2018 | 15 | 0.040 |
Why?
| Infant | 4 | 2020 | 9016 | 0.040 |
Why?
| Glucose | 1 | 2023 | 1000 | 0.040 |
Why?
| Cluster Analysis | 1 | 2020 | 481 | 0.040 |
Why?
| DNA-Binding Proteins | 1 | 2005 | 1443 | 0.040 |
Why?
| Proportional Hazards Models | 2 | 2013 | 1201 | 0.040 |
Why?
| Alginates | 1 | 2018 | 46 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 813 | 0.040 |
Why?
| Reproducibility of Results | 2 | 2021 | 3067 | 0.040 |
Why?
| Intercellular Junctions | 1 | 2017 | 39 | 0.040 |
Why?
| Ultrasonography | 2 | 1999 | 713 | 0.040 |
Why?
| Longitudinal Studies | 1 | 2025 | 2713 | 0.040 |
Why?
| Age Factors | 2 | 2016 | 3137 | 0.040 |
Why?
| Collagen | 1 | 2020 | 434 | 0.040 |
Why?
| beta Catenin | 1 | 2019 | 220 | 0.030 |
Why?
| Aorta | 1 | 2000 | 411 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2018 | 274 | 0.030 |
Why?
| Multilevel Analysis | 1 | 2017 | 27 | 0.030 |
Why?
| Netherlands | 1 | 2017 | 77 | 0.030 |
Why?
| Structure-Activity Relationship | 1 | 2018 | 548 | 0.030 |
Why?
| Protein Kinase Inhibitors | 2 | 2018 | 889 | 0.030 |
Why?
| Biocompatible Materials | 1 | 2020 | 395 | 0.030 |
Why?
| Incidence | 3 | 2011 | 2638 | 0.030 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2018 | 2071 | 0.030 |
Why?
| Indoles | 1 | 2019 | 383 | 0.030 |
Why?
| Cell Movement | 1 | 2021 | 941 | 0.030 |
Why?
| Molecular Dynamics Simulation | 1 | 2018 | 217 | 0.030 |
Why?
| Gene Editing | 1 | 2017 | 68 | 0.030 |
Why?
| Membrane Potentials | 1 | 2017 | 291 | 0.030 |
Why?
| Heredity | 1 | 2015 | 12 | 0.030 |
Why?
| Chi-Square Distribution | 1 | 2017 | 515 | 0.030 |
Why?
| Sodium | 1 | 2017 | 202 | 0.030 |
Why?
| Lod Score | 1 | 1995 | 66 | 0.030 |
Why?
| CRISPR-Cas Systems | 1 | 2017 | 109 | 0.030 |
Why?
| Recovery of Function | 1 | 2019 | 640 | 0.030 |
Why?
| Genes, Recessive | 1 | 1995 | 76 | 0.030 |
Why?
| Microscopy, Electron, Scanning | 1 | 2015 | 195 | 0.030 |
Why?
| Cadherins | 1 | 2017 | 188 | 0.030 |
Why?
| Hospitalization | 1 | 2025 | 2069 | 0.030 |
Why?
| Single-Cell Analysis | 1 | 2017 | 276 | 0.030 |
Why?
| Exons | 2 | 2008 | 342 | 0.030 |
Why?
| Hypertrophy, Right Ventricular | 1 | 1995 | 145 | 0.030 |
Why?
| Genes, Immunoglobulin | 1 | 1994 | 28 | 0.030 |
Why?
| Introns | 1 | 1996 | 251 | 0.030 |
Why?
| Mutagenesis | 1 | 2015 | 181 | 0.030 |
Why?
| Viscosity | 1 | 2015 | 90 | 0.030 |
Why?
| Mutant Proteins | 1 | 2015 | 99 | 0.030 |
Why?
| Enterovirus Infections | 2 | 1994 | 171 | 0.030 |
Why?
| Cytochalasins | 1 | 2014 | 3 | 0.030 |
Why?
| HEK293 Cells | 1 | 2017 | 693 | 0.030 |
Why?
| RNA Splicing | 1 | 1996 | 262 | 0.030 |
Why?
| Body Temperature | 1 | 2014 | 212 | 0.030 |
Why?
| Translocation, Genetic | 1 | 1994 | 97 | 0.030 |
Why?
| Major Histocompatibility Complex | 1 | 1994 | 230 | 0.030 |
Why?
| Gene Expression Regulation, Viral | 1 | 1994 | 90 | 0.030 |
Why?
| Tubulin | 1 | 2015 | 137 | 0.030 |
Why?
| Cause of Death | 1 | 2015 | 392 | 0.030 |
Why?
| Cardiac Myosins | 1 | 2013 | 30 | 0.030 |
Why?
| Morbidity | 1 | 2014 | 301 | 0.030 |
Why?
| Turner Syndrome | 1 | 1994 | 52 | 0.030 |
Why?
| Ventricular Fibrillation | 1 | 2013 | 57 | 0.030 |
Why?
| Receptors, Immunologic | 1 | 1994 | 216 | 0.030 |
Why?
| Electrophysiology | 1 | 2013 | 210 | 0.030 |
Why?
| Formaldehyde | 1 | 2013 | 60 | 0.030 |
Why?
| Skin | 1 | 2017 | 721 | 0.030 |
Why?
| Age of Onset | 1 | 2014 | 495 | 0.030 |
Why?
| In Vitro Techniques | 1 | 2014 | 1083 | 0.020 |
Why?
| Severity of Illness Index | 2 | 2015 | 2736 | 0.020 |
Why?
| Cell Survival | 1 | 2015 | 1085 | 0.020 |
Why?
| Lymphatic Diseases | 1 | 2012 | 21 | 0.020 |
Why?
| Mediastinal Diseases | 1 | 2012 | 10 | 0.020 |
Why?
| Mice, Knockout | 1 | 2019 | 2856 | 0.020 |
Why?
| Pacemaker, Artificial | 1 | 2013 | 110 | 0.020 |
Why?
| Patient Selection | 1 | 2015 | 662 | 0.020 |
Why?
| Cattle | 1 | 2014 | 977 | 0.020 |
Why?
| Receptors, Adrenergic, beta | 1 | 1992 | 126 | 0.020 |
Why?
| Blood Pressure | 2 | 2016 | 1727 | 0.020 |
Why?
| Immune System | 1 | 1992 | 175 | 0.020 |
Why?
| Antibody Formation | 1 | 1992 | 290 | 0.020 |
Why?
| Observer Variation | 1 | 2011 | 314 | 0.020 |
Why?
| Carrier Proteins | 1 | 2013 | 740 | 0.020 |
Why?
| Drug Therapy, Combination | 2 | 2004 | 1037 | 0.020 |
Why?
| Endothelin-Converting Enzymes | 1 | 2009 | 10 | 0.020 |
Why?
| Aspartic Acid Endopeptidases | 1 | 2009 | 26 | 0.020 |
Why?
| Early Diagnosis | 1 | 2010 | 234 | 0.020 |
Why?
| Metalloendopeptidases | 1 | 2009 | 59 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2016 | 3211 | 0.020 |
Why?
| Endothelins | 1 | 2009 | 62 | 0.020 |
Why?
| Autoimmunity | 1 | 1994 | 862 | 0.020 |
Why?
| Solute Carrier Family 22 Member 5 | 1 | 2008 | 9 | 0.020 |
Why?
| Linkage Disequilibrium | 1 | 2009 | 257 | 0.020 |
Why?
| Cricetulus | 1 | 2008 | 106 | 0.020 |
Why?
| Death, Sudden | 1 | 1987 | 24 | 0.020 |
Why?
| CHO Cells | 1 | 2008 | 152 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 1988 | 159 | 0.020 |
Why?
| Cricetinae | 1 | 2008 | 277 | 0.020 |
Why?
| Amyloidosis | 1 | 1987 | 40 | 0.020 |
Why?
| Genetic Carrier Screening | 1 | 2007 | 26 | 0.020 |
Why?
| Frameshift Mutation | 1 | 2006 | 32 | 0.020 |
Why?
| Electroretinography | 1 | 2006 | 44 | 0.020 |
Why?
| Pigment Epithelium of Eye | 1 | 2006 | 34 | 0.020 |
Why?
| Algorithms | 1 | 2013 | 1618 | 0.020 |
Why?
| Visual Fields | 1 | 2006 | 87 | 0.020 |
Why?
| Models, Genetic | 1 | 2009 | 594 | 0.020 |
Why?
| Fluorescein Angiography | 1 | 2006 | 143 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2007 | 400 | 0.020 |
Why?
| Terminology as Topic | 2 | 1999 | 203 | 0.020 |
Why?
| Antimetabolites | 1 | 2004 | 23 | 0.010 |
Why?
| Growth Inhibitors | 1 | 2004 | 44 | 0.010 |
Why?
| Societies, Medical | 1 | 2009 | 747 | 0.010 |
Why?
| Azathioprine | 1 | 2004 | 50 | 0.010 |
Why?
| Coxsackievirus Infections | 1 | 1984 | 13 | 0.010 |
Why?
| Calcineurin Inhibitors | 1 | 2004 | 68 | 0.010 |
Why?
| Everolimus | 1 | 2004 | 86 | 0.010 |
Why?
| Mycophenolic Acid | 1 | 2004 | 109 | 0.010 |
Why?
| Protein Isoforms | 1 | 2005 | 390 | 0.010 |
Why?
| Chromatography, Liquid | 1 | 2005 | 415 | 0.010 |
Why?
| Cyclosporine | 1 | 2004 | 259 | 0.010 |
Why?
| Tacrolimus | 1 | 2004 | 192 | 0.010 |
Why?
| Colorado | 1 | 2013 | 4412 | 0.010 |
Why?
| Protein Structure, Tertiary | 1 | 2005 | 837 | 0.010 |
Why?
| Captopril | 1 | 1983 | 10 | 0.010 |
Why?
| Comorbidity | 1 | 2008 | 1545 | 0.010 |
Why?
| Sirolimus | 1 | 2004 | 264 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 783 | 0.010 |
Why?
| Proline | 1 | 1983 | 76 | 0.010 |
Why?
| Probability | 1 | 2003 | 306 | 0.010 |
Why?
| Statistics, Nonparametric | 1 | 2003 | 421 | 0.010 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2004 | 395 | 0.010 |
Why?
| Adrenal Cortex Hormones | 1 | 2004 | 519 | 0.010 |
Why?
| Risk | 1 | 2003 | 854 | 0.010 |
Why?
| Hypertension, Pulmonary | 1 | 1992 | 1891 | 0.010 |
Why?
| Enterovirus B, Human | 2 | 1993 | 25 | 0.010 |
Why?
| Chronic Disease | 1 | 1985 | 1713 | 0.010 |
Why?
| Echocardiography, Doppler | 1 | 1999 | 108 | 0.010 |
Why?
| World Health Organization | 1 | 1998 | 110 | 0.010 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 198 | 0.010 |
Why?
| Survival Analysis | 2 | 1991 | 1271 | 0.010 |
Why?
| Cross-Over Studies | 1 | 1999 | 521 | 0.010 |
Why?
| Oxygen Consumption | 1 | 1999 | 672 | 0.010 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1995 | 87 | 0.010 |
Why?
| Organ Specificity | 1 | 1995 | 295 | 0.010 |
Why?
| Receptors, Interleukin | 1 | 1994 | 43 | 0.010 |
Why?
| Gene Amplification | 1 | 1994 | 105 | 0.010 |
Why?
| Receptors, Fc | 1 | 1994 | 52 | 0.010 |
Why?
| Genome, Viral | 1 | 1994 | 129 | 0.010 |
Why?
| Fathers | 1 | 1994 | 48 | 0.010 |
Why?
| Virology | 1 | 1993 | 23 | 0.010 |
Why?
| Sequence Homology, Nucleic Acid | 1 | 1993 | 150 | 0.010 |
Why?
| Evaluation Studies as Topic | 1 | 1993 | 170 | 0.010 |
Why?
| Interleukins | 1 | 1994 | 241 | 0.010 |
Why?
| Iodocyanopindolol | 1 | 1992 | 11 | 0.010 |
Why?
| Pindolol | 1 | 1992 | 15 | 0.010 |
Why?
| Neuropeptide Y | 1 | 1992 | 14 | 0.010 |
Why?
| Receptors, Adrenergic, alpha | 1 | 1992 | 31 | 0.010 |
Why?
| Adenylyl Cyclases | 1 | 1992 | 83 | 0.010 |
Why?
| Species Specificity | 1 | 1993 | 574 | 0.010 |
Why?
| Catecholamines | 1 | 1992 | 96 | 0.010 |
Why?
| Isoproterenol | 1 | 1992 | 112 | 0.010 |
Why?
| Autoantigens | 1 | 1994 | 417 | 0.010 |
Why?
| Complement System Proteins | 1 | 1994 | 313 | 0.010 |
Why?
| Promoter Regions, Genetic | 1 | 1996 | 1206 | 0.010 |
Why?
| DNA, Viral | 1 | 1993 | 349 | 0.010 |
Why?
| Receptors, Antigen, T-Cell | 1 | 1994 | 704 | 0.010 |
Why?
| Felodipine | 1 | 1988 | 4 | 0.000 |
Why?
| Nitrendipine | 1 | 1988 | 13 | 0.000 |
Why?
| Nisoldipine | 1 | 1988 | 7 | 0.000 |
Why?
| Nicardipine | 1 | 1988 | 6 | 0.000 |
Why?
| Transcription, Genetic | 1 | 1995 | 1415 | 0.000 |
Why?
| Diltiazem | 1 | 1988 | 28 | 0.000 |
Why?
| Nifedipine | 1 | 1988 | 29 | 0.000 |
Why?
| Verapamil | 1 | 1988 | 41 | 0.000 |
Why?
| Statistics as Topic | 1 | 1989 | 306 | 0.000 |
Why?
| Infant, Newborn | 1 | 1999 | 5753 | 0.000 |
Why?
| Autoantibodies | 1 | 1994 | 1466 | 0.000 |
Why?
| Cardiomyopathy, Alcoholic | 1 | 1985 | 1 | 0.000 |
Why?
| Pregnancy Complications, Cardiovascular | 1 | 1985 | 78 | 0.000 |
Why?
| Physical Exertion | 1 | 1986 | 205 | 0.000 |
Why?
| Heart Septal Defects | 1 | 1984 | 7 | 0.000 |
Why?
| Cardiac Catheterization | 1 | 1987 | 517 | 0.000 |
Why?
| Cardiac Output | 1 | 1984 | 156 | 0.000 |
Why?
| Vascular Resistance | 1 | 1984 | 370 | 0.000 |
Why?
| Coronary Disease | 1 | 1984 | 385 | 0.000 |
Why?
| Ethanol | 1 | 1985 | 587 | 0.000 |
Why?
| Antibodies, Viral | 1 | 1984 | 601 | 0.000 |
Why?
| Hypertension | 1 | 1985 | 1240 | 0.000 |
Why?
|
|
Mestroni's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|